MicroRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1

Richa Singh, Vikas Yadav, Sachin kumar & Neeru Saini

De novo lipogenesis, a hallmark for cancers is required for cellular transformation. Further it is believed that resistance to apoptosis and epithelial-to-mesenchymal-transition (EMT) facilitates metastasis via over-expression of anti-apoptotic Bcl-2. Previously we demonstrated that hsa-miR-195 targets BCL2, induces apoptosis and augmented the effect of etoposide in breast cancer cells. However, the mechanism behind its function remains elusive. Herein gene expression profiling was done in presence/absence of hsa-miR-195 in Breast cancer cells. IPA revealed mitochondrial dysfunction, fatty acid metabolism and xenobiotic metabolism signalling among the top processes being affected. For the first time we herein identified ACACA, FASN (the key enzymes of de novo fatty acid synthesis), HMGCR (the key enzyme of de novo cholesterol synthesis) and CYP27B1 as direct targets of hsa-miR-195. We further showed that ectopic expression of hsa-miR-195 in MCF-7 and MDA-MB-231 cells not only altered cellular cholesterol and triglyceride levels significantly but also resulted in reduced proliferation, invasion and migration. We further demonstrated that over expression of hsa-miR-195 decreased the Mesenchymal markers expression and enhanced Epithelial markers. In conclusion we say that hsa-miR-195 targets the genes of de novo lipogenesis, inhibits cell proliferation, migration, and invasion which potentially opens new avenues for the treatment of breast cancer.

Breast cancer is currently the leading cause of cancer death among women worldwide. ER+ subtype (Estrogen receptor or hormone receptor subtype) is the most vital discriminator of breast cancer, accounting for nearly 75% of all breast cancer cases1. Therapy approaches include irradiation and surgery, with chemotherapy considered an important strategy to treat breast cancer. It is believed that during chemotherapy, drug resistance frequently develops and impairs the successful treatment of breast cancer. In addition there is a need for new therapeutic targets as hormonal therapy is facing challenges against ER patients as well as acquired drug resistance in ER+ patients2.

Literature reveals that highly proliferating cancer cells need to synthesize fatty acids de novo for membrane and energy production. De novo fatty-acid synthesis involves two key enzymes, acetyl-CoA carboxylase (ACACA) and fatty-acid synthase (FASN). In normal tissues de novo fatty-acid synthesis is usually suppressed, and FASN expression is maintained at low levels whereas in cancer, the cells are highly dependent on the de novo synthesis3. Recently small-molecule BCL-2 inhibitors (ABT-737 etc) and FASN inhibitors such as cerulenin, C75 and orlistat have been shown to induce apoptosis in breast cancer.

Functional Genomics Unit, CSIR-Institute of Genomics and Integrative Biology (IGIB). Council of Scientific & Industrial Research (CSIR), Delhi, India. Correspondence and requests for materials should be addressed to N.S. (email: nsaini@igib.in)
cancer cells both in vitro and in vivo but heterogeneity of tumor and complexity of signalling pathways remains a major hurdle for effective cancer therapy. Hence there is an urgent need to identify a new generation of anticancer agents.

Micro RNAs (miRNAs) have emerged as key therapeutic agents against cancers and sufficient evidences are there to show that dysregulation of miRNAs also leads to drug resistance in different cancers and correction of these miRNAs using miRNA mimics or antagomiRs can normalize the gene regulatory network and signaling pathways and sensitize cancerous cells to chemotherapy and may provide exciting opportunities for cancer therapy.

We and others previously reported that hsa-miR-195 negatively regulates BCL2 expression by binding to its 3’ UTR. Multiple studies have also shown that hsa-miR-195 regulates biological processes like apoptosis, cell cycle and proliferation by targeting CDK4, CDK6, cyclin D1, cyclin E1, E2F3, E2F5 and WEE11-13. Yang G et al. recently showed that expression of miR-195 is low in breast cancer cells (and multidrug-resistant breast cancer tissues) and upregulation of miR-195 increases the sensitivity of breast cancer cells towards chemotherapeutic drug adriamycin.

Results of our study as well as the previous studies suggested the therapeutic potential of this miRNA however despite these studies it remains unclear how the cell's transcriptome responds to the presence/absence of hsa-miR-195. To understand how hsa-miR-195 exerts regulatory effects we herein, performed gene expression profiling using an Illumina microarray in MCF-7 and -231 cells in presence of hsa-miR-195 or hsa-miR-195 inhibitor (antimiR-195).

In this study, we used two breast cancer cell lines MCF-7 cells (rapidly growing tumor cells that are ER-positive, E-cadherin positive and noninvasive) and MDA-MB-231 (invasive and metastatic tumor cells) that are ER-negative and lacks E-cadherin. Hence, we identified and validated key genes of the de novo lipogenesis as direct targets of hsa-miR-195. Over expression of hsa-miR-195 downregulated and silencing of hsa-miR-195 by antimiR-195 up regulated the expression of ACACA, FASN and 3-Hydroxy-3-Methyl glutaryl CoA reductase (HMGCR), Cytochrome P450 family 27, subfamily B, polypeptide 1 (CYP27B1), a member of the cytochrome P450 superfamily respectively in breast cancer cells. Over-expression of hsa-miR-195 in these cells reduced the cellular cholesterol and triglyceride levels whereas inhibition of endogenous hsa-miR-195 enhanced these metabolites significantly. Our findings provide evidence that microRNA-195 attenuates epithelial-mesenchymal transition (EMT) in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1 and strongly suggest that overexpression of miR-195 may have therapeutic value in treating breast cancer.

Results

Transcriptome profiling and Ingenuity Pathway Analysis identifies mitochondrial dysfunction and lipid metabolism as the most significant pathways influenced by hsa-miR-195 in MCF-7 cells. Previously our lab has highlighted the therapeutic potential of hsa-miR-195 as an anticancer agent. However, to fully establish its therapeutic function it is necessary to further characterize hsa-miR-195. We herein performed genome-wide gene expression profiling of transfected (miR-195/antimiR-195) and untransfected MCF-7 cells and MDA-MB-231 cells using Illumina HT12 v4 gene expression beadchip. As shown in Fig. 1A, we first checked the endogenous levels as well as the over expression and depletion efficiency of miR-195 in MCF-7 and MDA-MB-231 cells respectively. Consistent to our previous findings, TaqMan based real time PCR assay showed that hsa-miR-195 over expression increases the levels of mature form of hsa-miR-195 by 2.5-fold (p value 0.03) and by 4.58-fold (p value 0.04) and significant decrease in the mature form of hsa-miR-195 after anti-miR-195 transfection in MCF-7 and MDA-MB-231 cells. We next performed illumina, as shown in schema (Fig. 1B). Analysis of the array data of MCF-7 cells by Illumina Bead Studio software showed 1418 (622 downregulated, mean fold change <0.66; 796 upregulated, mean fold change >1.5) differentially expressed genes (DEG) after over expression of hsa-miR-195 and 428 (DEG) after inhibition of hsa-miR-195 (353 genes were upregulated; mean fold change >1.5;75 genes downregulated; mean fold change <0.66) in MCF-7 cells (Supplementary Figure). The data obtained have been deposited in NCBI's Gene Expression Omnibus (GEO Series accession number GSE43656). Supplementary Table S2 and S3 show a list of differentially expressed genes that were found in the presence or absence of hsa-miR-195 in MCF-7 cells. To identify functional relationships among the differentially expressed genes, datasets representing genes with altered expression profile derived from microarray analysis were imported into the Ingenuity Pathway Analysis tool (IPA Version 8.8). In IPA differentially expressed genes are mapped to genetic networks available in the ingenuity database and then ranked by score. A network is a graphical representation of the molecular relationships between molecules. Supplementary Table S5 and S6 shows the top associated networks after over expression or inhibition of hsa-miR-195 in MCF-7 cells. Top Tox list tool of IPA was used to calculate a p-value, determining the probability that each toxicity list assigned to that dataset is not random. Figure 1C (lower panel) shows the top Tox lists obtained from the IPA that were most significant to the dataset of hsa-miR-195 over-expressed and depleted MCF-7 cells respectively. In our analysis, IPA Tox list revealed a significant enrichment of mitochondrial dysfunction, mechanism of gene regulation by peroxisome proliferators via PPAR-alpha, fatty acid metabolism, cholesterol metabolism and xenobiotic metabolism signalling after over-expression or depletion of hsa-miR-195 in MCF-7 cells.
Simultaneously profiling was also done in MDA-MB-231 cells in presence and absence of miR-195 and we found 300 (DEG) after over expression of hsa-miR-195 and 219 (DEG) after inhibition of hsa-miR-195 (Supplementary Figure S2 and Supplementary Table S7-S8). Similar to MCF-7 cells, Tox list of Ingenuity pathway analysis also revealed a significant enrichment of mechanism of gene regulation by peroxisome proliferators via PPAR-alpha and cholesterol biosynthesis (data not shown).

Over-expression of miR-195 leads to mitochondrial dysfunction. Mitochondria is known to play a central role in energy supply for normal cell function and also perform many important cellular physiology tasks such as induction of apoptosis, cellular calcium level and redox homeostasis. Our earlier study and current IPA analysis pointed towards mitochondrial dysfunction in hsa-miR-195 induced apoptosis^10. To further confirm the role of hsa-miR-195 in regulating mitochondrial dysfunction we first used the indicator TMRE (sensor of mitochondrial inner membrane potential), which is taken up by the mitochondria in a membrane potential dependent manner. Our results demonstrated significant decrease in orange-red fluorescence in hsa-miR-195 over-expressed MCF-7 and MDA-MB-231 cells as compared to scrambled control transfected cells (Fig. 2Ai). Differential sensitivity of miR-195 overexpressing or anti-miR expressing cells towards the mitochondrial function inhibitors like oligomycin, rotenone and sodium azide was also investigated and interestingly electron transport chain (ETC) inhibitors augmented the effect of miR-195 whereas no change in the mitochondrial membrane potential was observed when MCF-7 and MDA-MB-231 cells were transfected with anti-miR-195 (Fig. 2Aii).

We further examined the effect of alterations of hsa-miR-195 on calcium levels. Breast cancer cells were dual labelled with mitochondrial calcium specific dye, Rhod-2AM, and mitochondria specific dye MitoTracker Green and as shown in Fig. 2B (Supplementary Figure S2 iii), over-expression of hsa-miR-195 led to significant increase in mitochondrial calcium as compared to control and anti-miR-195 transfected MCF-7 and MDA-MB-231 cells. Simultaneously, the cytosolic calcium levels were also measured using Fluo-3AM dye as described in Materials and Methods and we found significant increase in Fluo-3 AM fluorescence after hsa-miR-195 overexpression in MCF-7 and MDA-MB-231 cells, whereas anti-miR-195 transfection showed insignificant change in the cytosolic calcium levels as compared to control (Fig. 2C).
Taken together all these findings confirmed that over-expression of hsa-miR-195 leads to mitochondrial dysfunction and calcium might play a role in it. Role of calcium in this needs further investigation.

**Hsa-miR-195 plays an important role in regulating lipid homeostasis.** To decipher the role of hsa-miR-195 in regulating lipid homeostasis, we first examined the effect of hsa-miR-195 over-expression or inhibition on the cellular levels of cholesterol and triglycerides. We observed statistically significant decrease after overexpression of hsa-miR-195 and increase after antimiR-195 transfection (Fig. 3A) of cholesterol as well as triglyceride levels in MCF-7 cells as compared to scrambled control transfected cells.

We further asked how miR-195 regulated lipid homeostasis (cholesterol as well as triglyceride levels). Several studies suggest that PPARs, liver-X receptors (LXRs) and sterol-response element–binding protein (SREBP) transcription factors regulate lipid homeostasis. Simultaneously there are also reports that SREBPs regulate the expression of genes involved in cholesterol biosynthesis (HMGCS1, HMGCR), cellular uptake (LDLR) and cellular efflux (ATP-binding cassette transporters, ABCA1, ABCG1 and ABCG5). Hence, we next examined the transcript levels of PPAR-α, PGC1-α (PPAR gamma coactivator 1-alpha), RXR-α, LXR-α, LXR-β, SREBP2, HMGCS1, HMGCR, LDLR, ABCA1, ABCG1, ABCG5, ACACA, FASN and CYP27B1 after over-expression or depletion of hsa-miR-195 in MCF-7 cells using real time PCR analysis (Fig. 3B). Interestingly, we observed significant decrease in the expression of FASN (2 fold, p < 0.05) and HMGCR (p < 0.05) after over-expression of hsa-miR-195. Additionally we observed an increase in the expression of SREBP2, ABCA1, ABCG1, LXR-β and LDLR in MCF-7 cells after anti-miR-195 treatment. There was no significant change in the expression of LXR-α and PPAR-α respectively.

In the current study cytosolic lipid droplets were also stained with Bodipy and as shown in Fig. 4A, we observed a significant decrease in cytosolic lipid droplets in hsa-miR-195 transfected MCF-7 cells as compared to scrambled control transfected cells.
compared to the cells transfected with scrambled control. On contrary, cytosolic lipid droplets increased substantially when the endogenous levels of hsa-miR-195 were depleted by antimiR-195. The scramble antimiR control did not show any significant changes. These results in addition to validating the analysis confirmed that hsa-miR-195 plays an important role in regulation of lipid homeostasis. In addition we also explored the effect of hsa-miR-195 on Caveolin-1 (CAV1), a scaffolding protein intimately involved with intracellular cholesterol trafficking and whose expression is highly dependent on the availability of cholesterol21,22. In MCF-7 cells we observed that over expression of hsa-miR-195 led to a 2.3-fold (P value = 0.034) decrease in the expression of CAV1 protein (Fig. 4B,C) as compared to scrambled transfected cells and antimiR-195 transfection rescued this effect. Literature reveals that CAV1 can have both cell survival and pro-apoptotic characteristics but the role of CAV1 in hsa-miR-195 induced apoptosis/cholesterol regulation needs further investigation.

Hsa-miR-195 targets key denovo fatty acid biosynthesis genes, ACACA and FASN. To understand the underlying molecular mechanism behind miR-195 mediated lipid homeostasis, we aimed to identify direct downstream targets of miR-195 using in-silico algorithm. TargetScan 6.2 revealed that key genes of denovo fatty acid biosynthesis, ACACA (ENST00000353139) and FASN (ENST00000306749) have predicted binding sites for hsa-miR-195 in their respective 3′UTRs. ACACA is the crucial rate-limiting enzyme in the fatty acid biosynthesis pathway catalysing the conversion of acetyl-CoA to malonyl-CoA, the first step in fatty acid biosynthesis23. FASN is the holozyme generating the basic fatty acid intermediate, palmitate, which is then processed into other longer chained fatty acids. Computational analysis further showed complete complementarity between seed region (2–8 nt) of hsa-miR-195 and the 1231–1237 nt of ACACA 3′UTR and this site and it was found to be conserved across several species (Supplementary Figure S1). Interestingly we also found that FASN has three predicted binding sites of hsa-miR-195 in its 3′UTR and the interspecies homology search showed that the these were conserved across different species of mammals (Supplementary Figure S1).
To validate ACACA or FASN as direct targets of miR-195 we obtained reporter constructs with luciferase coding sequence fused to 3′ UTR of ACACA/FASN respectively and employed a dual luciferase reporter assay in MCF-7 and MDA-MB-231 cells. Transfection analysis showed that overexpression of p195 led to a 50–65% decrease and antimiR-195 transfection (100 nM) led to a 25%–35% increase of luciferase activity of ACACA 3′ UTR in these cells (Fig. 5A). A non-specific mimic (cel-miR-67) did not affect luciferase activity of ACACA 3′ UTR construct. Similarly Fig. 5B shows that overexpression of p195 reduced the luciferase activity of FASN 3′ UTR reporter construct by 45–40% in MCF-7 and MDA-MB-231 cells as compared to only 3′ UTR transfected cells and this suppression was relieved by antimiR-195 transfection in both the cells. There was no significant change in luciferase activity when non-specific mimic was transfected.

The effect of miR-195 on protein levels of ACACA and FASN was also tested using western blot analysis. In agreement with the bioinformatic predictions and luciferase results overexpression of p195 led to 2-fold decrease in protein levels of ACACA and 1.7-fold decrease in protein levels of FASN (Fig. 5C,D) in MCF-7 cells. The protein levels of ACACA and FASN increased when antimiR-195 was cotransfected with p195. Similar results were obtained in MDA-MB-231 cells (Fig. 5C,D). Taken together all these results confirmed that hsa-miR-195 targets key genes of de novo fatty acid biosynthesis, ACACA and FASN.

Figure 4. Hsa-miR-195 regulates cellular lipid levels in MCF-7 cells. (A) (i) BODIPY staining of lipid droplets. Hsa-miR-195 overexpressed and depleted MCF-7 cells were stained with BODIPY and observed under confocal microscope for lipid droplets as described in Materials and Methods section. (ii) Fluorescence intensity was calculated by averaging the optical density over at least six region of interests in each sample. Bar graph shows mean fluorescence intensity (M.F.I) ± S.D of BODIPY of three independent experiments. **p < 0.01. here SAM means scramble anti-miR and AM means anti-miR. (B) Immunofluorescence assay of CAV1 in MCF-7 cells. Cells were transfected with 195 or antimiR-195 and 24 h post-transfection cells were fixed in 4% formaldehyde solution in PBS for 15 min. Cells were incubated with primary antibody (anti-CAV1 (Abcam, Cambridge, UK) for 2 h followed by Alexa Fluor 488-conjugated secondary antibody (Invitrogen) for 1 h. The fluorescence images were captured using Nikon microscope (Ti Eclipse) at 40x magnification under 488/519 nm excitation and emission wavelengths. Mean fluorescence intensity of CAV1 was calculated by averaging optical densities over six different regions of interest in each sample. Bar graph represents relative mean fluorescence intensity (M.F.I) ± S.D of three independent experiments. **P < 0.01. (C) Western blotting for detection of protein levels of CAV1 after overexpression/depletion of hsa-miR-195 in MCF-7 (ER-positive) cells. Bar graph in the lower panel shows mean fold change in CAV1 protein ± S.D of three independent experiments. *P < 0.05.
HMGCR the rate-limiting enzyme in the biosynthesis of cholesterol is a potential target of Hsa-miR-195. Target prediction using miRanda program identified an evolutionarily conserved binding site for hsa-miR-195 in 3′UTR of HMGCR, the enzyme catalyzing rate limiting step of cholesterol biosynthesis. We further observed complete complementarity between the 1388–1394 nt of HMGCR to 2–6 nt of hsa-miR-195 (Supplementary Figure S1). To assess whether HMGCR is a direct target of hsa-miR-195, a dual luciferase reporter assay was performed. As shown in Fig. 6A, overexpression of p195 in MCF-7 cells led to a reduction in luciferase activity by 48% as compared to that of only 3′UTR transfected cells and the antimiR-195 transfection rescued this downregulation in MCF-7 cells. There was no significant change in the luciferase activity when non-specific mimic was transfected. Similar results were obtained in MDA MB-231.

Our western blot analysis demonstrated 1.4-fold decrease in the expression of HMGCR in p195 transfected MCF-7 cells as compared to scrambled control (Fig. 6C). Cotransfection of antimiR-195 and p195 partially rescued this downregulation. Similar results were obtained in MDA-MB-231 (Fig. 6C). Our results confirmed that hsa-miR-195 targets HMGCR.

Hsa-miR-195 targets CYP27B1. TargetScan algorithm also identified hsa-miR-195 binding site in the 3′UTR of CYP27B1 (ENST00000481739) and 342–348 nt of CYP27B1 3′UTR was found to have perfectly complementary to the 2–8 nt seed region of hsa-miR-195 (Supplementary Figure S1). Dual luciferase reporter assay showed that overexpression of p195 led to a 34% reduction in luciferase activity (Fig. 6B) which was rescued in presence of antimiR-195. Our real time PCR data showed no significant changes in CYP27B1 mRNA levels after hsa-miR-195 overexpression, but inhibition of hsa-miR-195 by antimiR-195 led to a 1.6-fold increase in CYP27B1 levels in MCF-7 cells (Fig. 3B). Furthermore, our western blot data showed 1.37-fold decrease in CYP27B1 protein levels after hsa-miR-195 overexpression.
in MCF-7 cells (Fig. 6D). Similar results were obtained in MDA-MB-231 (Fig. 6B–D). Our findings suggested that has-miR-195 also regulates CYP27B1 by directly binding to its 3′ UTR.

**Overexpression of has-miR-195 inhibits cell proliferation, migration, invasion and attenuates epithelial to mesenchymal transition in breast cancer cells.** MCF7 and MDA MB-231 cells transfected with miR-195 showed a significant reduction in cell proliferation at day 2 compared with cells transfected with scrambled control (P < 0.05) as measured by CFSE cell proliferation kit. However, MCF7 and MDA-MB-231 cells treated with palmitate had a higher rate of cell proliferation than cells transfected with miR-195 only (Fig. 7A, Supplementary Figure S3).

We next examined the effect of has-miR-195 on cell migration by wound healing assay. As expected in the has-miR-195 expressing MCF-7 and MDA-MB-231 cells, the rate of cell migration decreased considerably and the filling of the wound area was time dependent, thereby indicating that has-miR-195 treatment severely alters the migration ability of the cells (Fig. 7B, Supplementary Figure S4). The presence of palmitate reversed the miR-195 dependent changes in cell migration.

As shown in Fig. 7C the invasion ability of MDA MB-231 cells was inhibited after transfection with has-miR-195. On the contrary, the invasion ability of MDA MB-231 cells increased after treatment with palmitate (Supplementary Figure S5).

Previous studies have revealed that anticancer agents induce mesenchymal to epithelial transition (MET) in cancer cells. After having identified four main downstream targets of miR-195, we further examined which specific phenotype are regulated by miR-195 in breast cancer cells. We employed western blot to detect the expression of epithelial cell markers such as E-cadherin, ck8/18, claudin 1 and mesenchymal cell markers such as fibronectin, N-cadherin and p-vimentin. As shown in Fig. 7D, we found expression levels of fibronectin, p-vimentin and N-cadherin to be significantly decreased in the breast cancer cell lines after has-miR-195 overexpression. On contrary, the expression levels of E-cadherin, ck8/18, claudin-1 were increased in the breast cancer cell lines after has-miR-195 overexpression.
Together all these results demonstrated that the transient overexpression of hsa-miR-195 inhibited cell proliferation, migration, invasion and attenuates epithelial to mesenchymal transition in MCF-7 (Tumorigenic but non-metastatic) and MDA-MB-231 (Tumorigenic with high metastatic potential). Interestingly, in our array data also we found significant reduction of stemness-related genes such as BMI-1, SOX-2, Twist-1, GLI-2, CXCR7 and ALDH1A3 after miR-195 overexpression thereby strongly implicating role of hsa- miR-195 in inhibiting breast cancer stem cell-like self-renewal. However this molecular aspect of miR-195 needs further validation.

Discussion

Despite substantial progress in understanding the breast cancer signaling network, effective therapies remain scarce due to tumor heterogeneity, insufficient disruption of oncogenic pathways, drug resistance and drug-induced toxicity. Hence new and additional approaches are required for the treatment of breast cancer.

High proliferation rate has been the characteristic feature of cancer cells which renders their need for high levels of fatty acid as a substrate for energy production and membrane biogenesis25. Cancer cells prefer to derive their need for fatty acid via de novo lipogenesis in comparison to normal human tissues which prefers to utilize exogenous lipids, as a consequence of which cancer cells harbor high levels of FASN and ACACA. Comparatively among various cancer sub types, breast cancer cells significantly nurture very high levels of these key enzymes owing to their high proliferation, aggressiveness and metastatic potential26.

We and others have previously reported that hsa-miR-195 negatively regulates BCL2 expression and we also demonstrated that over-expression of hsa-miR-195 not only caused an increase in apoptosis but...
also augmented the death inducing effect of etoposide in breast cancer MCF-7 cells\textsuperscript{10}. In the current study we show that hsa-miR-195 targets key enzymes of the de novo lipogenesis pathways e.g., ACACA, FASN, HMGCGR and CYP27B1 by binding to their respective 3′UTRs.

ACACA and FASN are highly expressed in cancers and small molecules targeting these enzymes are being considered as potential therapeutic agents for therapy\textsuperscript{27–29}. FASN a multifunctional enzyme plays a key role in biosynthesis of fatty acid and ACACA is known to specifically interact with the protein coded by one of the major breast cancer susceptibility genes BRCA1\textsuperscript{30}. Furthermore, FASN is highly elevated in 30% of HER2 over-expressing breast cancers and considerable interest has developed in searching for novel FASN inhibitors as therapeutic agents for treatment of HER2-overexpressing breast also\textsuperscript{31}. In the current study we observed significant down regulation of ACACA and FASN after over-expression of hsa-miR-195 in MCF-7 and MDA-MB-231 cells. Recently Mao et al. have shown that miR-195 also inhibits cell invasion and migration by down-regulating FASN in osteosarcoma cells\textsuperscript{32}. Similar to Mao et al. in the current study we also observed that over expression of hsa-miR-195 in breast cancer cells inhibited cell migration, invasion and cell proliferation. We also observed that transient over-expression of hsa-miR-195 inhibited cell invasion in MDA-MB-231 cells. Simultaneously our work also identifies hsa-miR-195 as a regulator of cholesterol metabolism. We observed that hsa-miR-195 targets the rate-limiting enzyme of the mevalonate pathway, HMGC, by binding to its 3′UTR and down regulating its protein levels. Our experimental findings showed that antimiR-195 treatment not only leads to increase in HMGC and HMGC51 mRNA levels but also leads to significant increase in the cholesterol levels. Several recent studies show that aberrant regulation of cholesterol homeostasis has been associated with multiple types of cancer and literature also reveals that statins originally developed as cholesterol lowering drugs that target HMGC are currently being investigated as potential anticancer agents including breast cancer\textsuperscript{33,34}.

Our study also identified CYP27B1 to be a novel target of hsa-miR-195. CYP27B1 is a cytochrome P450-containing hydroxylase expressed in kidney and other tissues that generates active vitamin-D [1α, 25(OH)\textsubscript{2}D\textsubscript{3}] from an inactive vitamin-D precursor 25-hydroxycholecalciferol [25(OH)D\textsubscript{3}] and plays an important role in calcium homeostasis, steroid biosynthesis, xenobiotic metabolism etc\textsuperscript{35}. Interestingly recently Lopes N et al. observed that CYP27B1 is upregulated in breast tumours as compared with normal tissue\textsuperscript{36}. In our study we not only observed significant down regulation of CYP27B1 at the transcriptional as well as translational levels but also significant increase in the mitochondrial calcium levels in MCF-7 and MDA-MB-231 cells after over-expression of hsa-miR-195. Furthermore Ingenuity Pathway Analysis of our microarray data (GEO accession number GSE43656) showed CAR/RXR activation after antimiR-195 treatment and we show here that antimiR-195 treatment led to an increase in the expression of constitutive androstane receptor (NR1I3, CAR) and its target gene CYP2B6 at the transcriptional levels in MCF-7 and MDA-MB-231 cells. Since, CAR, a xenobiotic-activated transcription factor is found to be highly expressed in ERalpha-positive breast tumors; future studies in this direction may provide conclusive answers.

In conclusion, we hereby present a model (Fig. 8) which reveals that over-expression of hsa-miR-195 leads to a decrease in cholesterol and fatty acid biosynthesis and vice versa by targeting key regulatory genes of both of these pathways. We also speculate that changes in the hsa-miR-195 levels might also change the expression of the genes involved in xenobiotic and vitamin D metabolism. Further studies in this direction may provide a conclusive answer.

The role of pro-apoptotic hsa-miR-195 in inhibiting de novo lipogenesis via targeting genes over-expressed in breast cancer (BCL-2, FASN, ACACA, HMGCGR, CYP27B1) makes hsa-miR-195 an effective anticancer molecule. The therapeutic potential of hsa-miR-195 for breast cancer is further strengthened by our migration/wound healing, cell proliferation assay and EMT immunoblot assay. The results in current study provide a detailed insight into functional role of hsa-miR-195 and we believe that hsa-miR-195 can be used as therapeutics for breast cancer. Still these findings remain open for investigation and future in vivo studies in this direction may provide conclusive answers. In addition our characterization of hsa-miR-195 enhances our understanding of intricate regulatory networks of cholesterol and fatty acid biosynthesis also. Although our findings point to the basic and translational relevance of miRNA, therapeutic in vivo manipulations of hsa-miR-195 are warranted.

Methods

Cell culture and transfections. Human Estrogen Receptor (ER)-positive MCF-7, (ER)-negative MDA-MB-231 breast cancer cells were procured from National Centre for Cell Sciences (NCCS), Pune, India and passaged in the lab. The cell lines were not reauthenticated by the authors. Cells were maintained in DMEM containing 10% (v/v) fetal calf serum, 100 Units/ml penicillin, 100 μg/ml streptomycin, 0.25 μg/ml amphotericin at 37 °C in a humidified atmosphere at 5% CO\textsubscript{2}. Transfections were done using Lipofectamine 2000/Lipofectamine LTX-Plus (Invitrogen, CA, USA) reagent according to manufacturer’s protocol.

Over expression and knock down of hsa-miR-195. For over-expression of hsa-miR-195, a 237 bp region harbouring pre-miR-195 was cloned in pSilencer 4.1 vector (Ambion, Austin, TX, USA) and called p195 throughout the manuscript. Scramble control is a pSilencer 4.1 plasmid containing a scrambled sequence (which has limited homology to known human or mouse sequences) was used as negative
control in the experiments. For experiments with antimiR-195, anti-miRTM miRNA inhibitor of miR-195 was purchased from Ambion (Austin, TX). An antimiR miRNA inhibitor negative control (AM17010) (Ambion, Austin, Texas) having a random sequence validated to produce no identifiable effects on known functions of miRNAs was used and was called SAM. 24 h post transfection cells were harvested by trypsinization and used.

Real-time PCR. Total RNA was extracted with the Trizol reagent (Invitrogen, USA) and reverse transcribed using M-MuLV reverse transcriptase as per the manufacturer’s instructions (Fermentas, USA). TaqMan microRNA assays (Applied Biosystems, CA, USA) that include specific RT primers and TaqMan probes were used to quantify the expression of mature miR-195 (AB Assay ID 000494), as described by the manufacturer. 18S rRNA (AB Assay ID 4333760F) was used for normalization. Primers used for detection of expression levels of ACACA, FASN, HMGCR, CYP27B1, HMGC51, SREBP1, SREBP2, PGC1-α, PPAR-α, LXR-α, RXR-α, IDI1, SQLE, LDLR, ABCA1, ABCG1, ABCG5, NR1L3 (CAR), CYP2B6 and 18S rRNA are listed in Supplementary Table S1. The real-time PCR data was analyzed using Pfaffl’s method37.

Illumina microarray and Ingenuity pathway analysis. Genome-wide expression profiling was performed using Illumina HumanHT-12 v4 BeadChips (Illumina, CA, USA) representing 47231 human transcripts in three biological replicates of untransfected, miR-195 over expressed and miR-195 depleted (100 nM antimiR-195) MCF-7 and MDA-MB-231 cells as described previously38. Data was normalized by rank invariant method and the genes which crossed the threshold of detection p value ≤ 0.05 among all the samples and differential score p value ≤ 0.05 among the test samples were considered to be differentially expressed genes and selected for further investigation. The data obtained has been deposited in NCBI’s Gene Expression Omnibus and is accessible through the Gene Expression Omnibus Series accession number GSE43656. Datasets representing genes with altered expression profile derived from microarray analyses were imported into the Ingenuity Pathway Analysis Tool (IPA Tool; Ingenuity® Systems, Redwood City, CA USA; http://www.ingenuity.com) and analysed as described previously39.

Tetramethylrhodamine ethyl ester (TMRE) staining for mitochondrial membrane potential. Mitochondrial membrane potential was measured using TMRE (Molecular Probes, OR, USA) according to the manufacturers’ protocol. TMRE is a cell permeant, positively charged, red-orange dye...
that readily accumulates in active mitochondria due to their relative negative charge. Depolarized or inactive mitochondria have decreased membrane potential and fail to sequester TMRE. Consequently, mitochondrial depolarization is indicated by a decrease in the red fluorescence intensity. Briefly, transfected or untransfected cells were stained with TMRE dye at a final concentration of 100 nM for 20 min in dark at 37 °C and then harvested by trypsinization. Cells were washed with 1× PBS and then the red fluorescence was measured by flow cytometry and analysed as done previously (Guava EasyCyte, Millipore). A total of 5,000 events were counted. Wherever indicated Electron transport chain (ETC) inhibitors, such as rotenone (a complex I inhibitor), sodium azide (a complex IV inhibitor), and oligomycin (a complex V inhibitor) were also used.

**Cytosolic and mitochondrial calcium estimation.** The change in calcium ion concentration in the cytosol was determined using Fluo-3 AM (Santa Cruz Biotechnology, CA, USA). Fluo-3 acetoxymethyl (AM) ester is a cell permeable analog of Fluo-3. After crossing the membrane, the product is quickly metabolized by cytoplasmic esterases to the membrane impermeant Fluo-3 a fluorescence chelator which when excited by visible light (~488 nm) emits a green fluorescence (~525 nm) upon binding with calcium ions. It does not emit fluorescence unless bound to calcium ions. The cells grown in 12-well plates were washed three times with ice-cold HEPES-buffered Hank’s balanced salt solution (HBSS) and were loaded with 0.5 μM Fluo-3 AM in HBSS for 20 min at 37 °C in the dark. After the incubation, twice the volume of HBSS was added to it and cells were further incubated for 40 min. The cells were then washed with HBSS and kept at 37 °C for 10 min. Following this, the cells were trypsinized and fluorescence was detected using Flow cytometer (Guava Technologies, Hayward, CA, USA). A minimum of 5,000 events were counted.

To detect mitochondrial calcium levels, Rhod-2 AM (Invitrogen, CA, USA) dissolved in DMSO was used. MCF-7 and MDA-MB-231 cells were incubated with fresh medium containing 2 μM of Rhod-2 AM for 30 min in dark and then after two washings of 10 min each a further counterstaining with 200 nM MitoTracker Green (Invitrogen, CA, USA) was done at 37 °C for 10 min. Fluorescence images were obtained by fluorescent microscopy (Nikon Inc., NY USA) at 60× magnification under corresponding excitation and emission wave lengths.

**BODIPY staining of lipid droplets.** Cytosolic lipid droplets were stained using BODIPY 493/503 (4,4-Difluoro-1,3,5,7,8-Pentamethyl-4-Bora-3a,4a-Diaza-s-Indacene) (Molecular Probes, Invitrogen, CA USA) according to the manufacturers’ protocol. Cells were then mounted using Prolong Gold Anti-fade reagent (Invitrogen) and observed under 63× in Carl Zeiss LSM510 Meta confocal microscope. Images were acquired using Zen2000 software.

**Cellular cholesterol and triglycerides levels quantitation.** Cholesterol and triglyceride content was determined using cholesterol quantitation kit (Biovision, CA, USA) and Triglyceride quantification kit (BioVision) as mentioned earlier. In brief, 10⁶ cells were lysed and lipids were extracted by homogenization with 200 μl of chloroform: isopropanol: Triton X-100 (7:11:0.1). These lipid extracts were vacuum dried for 30 min and the residues were dissolved in 200 μl of cholesterol Reaction Buffer provided with the kit. Cholesterol was estimated by spectrophotometry at λ = 570 nm in a 96 well plate according to the manufacturer's instructions. For triglycerides levels quantitation, ~10 million cells were lysed in 1 ml solution containing 5% NP-40 in water and slowly heated to 80–100 °C. This extract was then used for fluorometric estimation at Ex/Em = 535/590 nm. Cholesterol and triglycerides content were normalized by total protein concentration.

**Immunofluorescence analysis.** Cells were seeded and grown on 25 × 25-mm cover slips in 6-well tissue culture plates. Next day, cells were transfected with p195 or anti-miR-195 and 24 h post-transfection, the cells were fixed in 4% formaldehyde solution in PBS for 15 min. Cells were permeabilized for 5 min in 0.1% Triton X-100 followed by 3 washes with 1× PBS. Cells were incubated in blocking buffer (1% BSA and 0.1% Triton X-100 in 1× PBS) for 1 h, primary antibody anti-CAV1 (Abcam, Cambridge, UK) for 2 h followed by Alexa Fluor 488-conjugated secondary antibody (Invitrogen) for 1 h. The fluorescence images were captured using inverted microscope Nikon ECLIPSE Ti (Nikon Corporation, Tokyo, Japan at 40× magnification under 488/519 nm excitation and emission wave lengths.

**Luciferase reporter assay.** 3′UTR reporter clones for ACACA, FASN, HMGCR and CYP27B1 were obtained from Origene (SC218496, SC210244, SC216360 and SC210195 respectively) and luciferase activity was measured using dual luciferase reporter assay system (Promega, Madison, WI, USA) as described previously.

**Protein preparation and Western blotting.** Cells were trypsinized and lysed with modified RIPA buffer (50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1% NP40, 0.25% Na-deoxycholate, 1 mM EDTA) containing protease inhibitors (1 μg/ml aprotinin, 1 μg/ml leupeptin, 1 μg/ml pepstatin, 1 mM PMSF, 1 mM sodium orthovanadate and 1 mM sodium fluoride) for 30 minutes on ice. The lysates were centrifuged at 16000 × g for 30 minutes at 4 °C and the supernatant was collected. Protein concentration was determined by BCA (Sigma, USA) method. Equal amount of proteins (30–50 μg) were separated on 12–15% sodium...
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to PVDF membrane (Mdli; Advanced Microdevices, India). Membrane was blocked using 5% skimmed milk for 1 h at RT and incubated with respective antibodies in 1% skimmed milk for 2–3 h followed by incubation with secondary antibody for 1 h. Primary antibody for FASN, Fibronectin, E-cadherin, N-cadherin were obtained from Santa Cruz (Santa Cruz Biotechnology, CA, USA). ACACA, CYP27B1, HMGCR, CAV1 were from Abcam (Cambridge, UK), claudin-1, CK8/18, p-Vimentin were from Cell signalling Tech (USA). β-actin and GAPDH were from Sigma (Sigma, USA). β-actin/GAPDH was used as normalizing controls. The primary antibody for β-actin was purchased from Sigma (Sigma, USA). The secondary antibodies were HRP-linked and blots were developed using enhanced chemiluminescence (Pierce, Amersham). Integrated density values were calculated using Alphalager 3400 (Alpha InnoTech, San Leandro, CA, USA). These values were then normalized to β-actin. All experiments were repeated at least three times; representative results are presented.

Palmitate-BSA Conjugate and cell treatment. Sodium palmitate (Sigma, MO, USA) was dissolved in 0.1 M NaOH by heating at 70°C for 20 min. Solution was then diluted with 10% fatty acid free-BSA (dissolved in autoclaved MilliQ water) and allowed to conjugate for 15 min at 55°C. Palmitate-BSA conjugate solution was filter sterilized and stored at −20°C for future use but were allowed to activate at 55°C for 10 min prior to use in cell culture. In all the experiments palmitate was used at a concentration of 100 μM.

Cell proliferation assay. To detect proliferation rate, MCF7 and MDA-MB-231 cells were transfected with p195 and in presence or absence of palmitate cells were labelled with 5 μM Carboxyfluorescein Diacetate (CFSE) dye (CellTrace™ CFSE Cell Proliferation Kit, C34554, Invitrogen) for 10 min at 37°C and the staining was ended by adding 5 volumes of ice-cold culture media to the cells. CFSE proliferation assay was performed on Days 0 and 2, and proliferation was measured using flow cytometry. The representative overlapped histogram is shown.

Wound healing assay. MCF7 and MDA-MB-231 cells were plated on a six-well tissue culture plate. The next day, cells were transfected with p195 or antimiR-195. After 24 h, the wound was artificially created by scraping with a sterilized pipette tip and the fresh media (in presence or absence of 100 μM palmitate) was added to the cells after washing with PBS respectively. The wound area was monitored for the next 2 days at an interval of 24 h. The microscopy images of the cells migrating in the wound area were taken at 10× magnification by Nikon Eclipse Ti microscope (Nikon, Tokyo, Japan). The quantitative values of the wound size were determined by web-based WimScratch module of Wimasis online software.

Cell invasion assay. Cell invasion assay was performed using BioCoat™ Matrigel Invasion Chamber (6-well Boyden chamber) procured from BD Biosciences and were hydrated with Serum-free medium for 2 h prior to seeding of the cells. Briefly, cells were transfected with miR-195 or AntimiR-195 for 24 h and then serum-starved for 6 h. Following suspension in serum-free media, cells were introduced in top chambers (~ 30,000 per well) and incubated at 37°C, 5% CO₂ incubator for 24 h. Lower chamber contains serum-loaded medium as attractant. Upon termination of the incubation, non invasive cells were removed carefully with a cotton swab and invasive cells were fixed with ethanol and stained using 0.05% Crystal Violet. After visualization through Nikon upright microscope, cells were lysed in 200 μL extraction buffer (Cell Biolab) and incubated for 10 min on an orbital shaker. Color developed thereafter was measured at 560 nM.

Statistical analysis. Results are given as mean of 3 independent experiments ± SD. An independent Student’s two-tailed t test was performed using replicate values. Values of P < 0.05 were considered statistically significant.

References
1. Zhang, M. H., Man, H. T., Zhao, X. D., Dong, N. & Ma, S. L. Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials. Biomed Rep. 2, 41–52 (2014).
2. Zhang, Y., Su, H., Rahimi, M., Tochihara, R. & Tang, C. EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PGR expression and modulation of apoptotic molecules in breast cancer. Int J Cancer. 125, 2021–2028 (2009).
3. Currie, E., Schulze, A., Zechner, R., Walther, T. C. & Farese, R. V. Cellular fatty acid metabolism and cancer. Cell Metab. 18, 153–161 (2013).
4. Pizer, E. S. et al. Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res. 56, 2745–2747 (1996).
5. Pizer, E. S. et al. Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res. 56, 1189–1193 (1996).
6. Zheng, L. et al. GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1. Cancer Lett. 309, 27–36 (2011).
7. Bartel, D. P. MicroRNAs: target recognition and regulatory functions. Cell. 136, 215–233 (2009).
8. Garzon, R., Calin, G. A. & Croce, C. M. MicroRNAs in Cancer. Annu Rev Med. 60, 167–179 (2009).
9. Chen, Y. Q. et al. MicroRNA-195 promotes apoptosis in mouse podocytes via enhanced caspase activity driven by BCL2 insufficiency. *Am J Nephrol.* 34, 549–559 (2011).
10. Singh, R. & Saini, N. Downregulation of BCL2 by miRNAs augments drug-induced apoptosis—a combined computational and experimental approach. *J Cell Sci.* 125, 1568–1578 (2012).
11. Bhattacharya, A. et al. Regulation of cell cycle checkpoint kinase WEE1 by miR-195 in malignant melanoma. *Oncogene.* 32, 3175–3183 (2013).
12. Lin, Y. et al. Cyclin-dependent kinase 4 is a novel target in microRNA-195-mediated cell cycle arrest in bladder cancer cells. *FEBS Lett.* 586, 442–447 (2012).
13. Xu, T. et al. MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. *Hepatology.* 50, 113–121 (2009).
14. Yang, G. et al. Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1. *Oncof Rep.* 30, 877–889 (2013).
15. Schirmann, S., Schwirzke, M., Brunner, N. & Weidle, U. H. Molecular analysis of two mammary carcinoma cell lines at the transcriptional level as a model system for progression of breast cancer. *Clin Exp Metastasis.* 16, 129–39 (1998).
16. Kirschmann, D. A., Seftor, E. A., Nieva, D. R., Mariano, E. A. & Hendrix, M. J. Differentially expressed genes associated with the metastatic phenotype in breast cancer. *Breast Cancer Res Treat.* 55, 127–36 (1999).
17. Caton, P. W., Holness, M. J., Bishop-Bailey, D. & Sugden, M. C. PPARalpha-LXR as a novel metabolostatic signalling axis in skeletal muscle that acts to optimize substrate selection in response to nutrient status. *Biochem J.* 437, 521–530 (2011).
18. Horton, J. D. Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis. *Biochem Soc Trans.* 30, 1091–1095 (2002).
19. Fielding, C. J., Bist, A. & Fielding, P. E. Cavelin mRNA levels are up-regulated by free cholesterol and down-regulated by oxysterols in fibroblast monolayers. *Proc Natl Acad Sci USA.* 94, 3753–3758 (1997).
20. Murata, M. et al. VIP21/cavelin is a cholesterol-binding protein. *Proc Natl Acad Sci USA.* 92, 10339–10343 (1995).
21. Ha, J. et al. Cloning of human acetyl-CoA carboxylase cDNA. *Eur J Biochem.* 219, 297–306 (1994).
22. Betel, D., Wilson, M., Gabow, A., Marks, D. S. & Sander, C. The microRNA.org resource: targets and expression. *Nucleic Acids Res.* 36, D149–D153 (2008).
23. Kuhajda, F. P. Fatty acid synthase and cancer: new application of an old pathway. *Cancer Res.* 66, 5977–5980 (2006).
24. Hunt, D. A., Lane, H. M., Zygmunt, M. E., Dervan, P. A. & Hennigar, R. A. mRNA stability and overexpression of fatty acid synthase in human breast cancer cell lines. *Anticancer Res.* 27, 27–34 (2007).
25. Chajes, V., Cambot, M., Moreau, K., Lenoir, G. M. & Joulin, V. Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival. *Cancer Res.* 66, 5287–5294 (2006).
26. Wolter, D., Desvergne, B. & Wahli, W. Roles of PPARs in health and disease. *Nature.* 405, 421–424 (2000).
27. Lund, E. G., Menke, J. G. & Sparrow, C. P. Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis. *Arterioscler Thromb Vasc Biol.* 23, 1169–1177 (2003).
28. Oliveras, G. et al. Novel anti-fatty acid synthase compounds with anti-cancer activity in HER2+ breast cancer. *Ann NY Acad Sci.* 1210, 86–92 (2010).
29. Orita, H., Coulter, J., Tully, E., Kuhajda, F. P. & Gabrielson, E. Inhibiting fatty acid synthase for chemoprevention of chemically induced lung cancers. *Clin Cancer Res.* 14, 2458–2464 (2008).
30. Sinilnikova, O. M. et al. Haplotype-based analysis of common variation in the acetyl-coA carboxylase alpha gene and breast cancer risk: a case-control study nested within the European Prospective Investigation into Cancer and Nutrition. *Cancer Epidemiol Biomarkers Prev.* 16, 409–415 (2007).
31. Sinilnikova, O. M. et al. Fatty acid synthase inhibition by amentoflavone suppresses HER2/neo (erbB2) oncogene in SKBR3 human breast cancer cells. *Phytother Res.* 27, 713–720 (2013).
32. Hao, J. H. et al. microRNA-195 suppresses osteosarcoma cell invasion and migration in vitro by targeting FASN. *Oncof Lett.* 4, 1125–1129 (2012).
33. Bjarnadottir, O. et al. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. *Breast Cancer Res Treat.* 138, 499–508 (2013).
34. Clendening, J. W. & Penn, L. Z. Targeting tumor cell metabolism with statins. *Oncogene.* 31, 4967–4978 (2012).
35. Dunbar, D. R. et al. Transcriptional and physiological responses to chronic ACTH treatment by the mouse kidney. *Physiol Genomics.* 40, 158–166 (2010).
36. Lopes, N. et al. Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. *BMC Cancer.* 10, 483 (2010).
37. Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res.* 29, e45 (2001).
38. Chhabra, R., Dubey, R. & Saini, N. Gene expression profiling indicate role of ER stress in miR-23a–27a–24-2 cluster induced apoptosis in HEK293T cells. *RNA Biol.* 8, 648–664 (2011).
39. Adlakha, Y. K. & Saini, N. miR-128 exerts pro-apoptotic effect in a p53 transcription-dependent and -independent manner via PUMA-Bak axis. *Cell Death Dis.* 4, e542 (2013).
40. Yadav, V., Varshney, P., Sultana, S., Yadav, J. & Saini, N. Moxifloxacin and ciprofloxacin induces S-phase arrest and augments apoptotic effects of cisplatin in human pancreatic cancer cells via ERK activation. *BMC Cancer.* 15, 581 (2015).
41. Adlakha, Y. K. et al. Pro-apoptotic microRNA-128-2 modulates ABCA1, ABCG1 and RXRalpha expression and cholesterol homeostasis. *Cell Death Dis.* 4, e780 (2013).
42. Chowdhari, S. & Saini, N. Irsa-mir-4516 mediated downregulation of STAT3/CDK6/UBE2N plays a role in PUVA induced apoptosis in keratinocytes. *J Cell Physiol.* 229, 1630–1638 (2014).
43. Yadav, V., Sultana, S., Yadav, J. & Saini, N. Gatifloxacin induces S and G2-phase cell cycle arrest in pancreatic cancer cells via p21/p27/p53. *PLoS One.* 7, e47796 (2012).
44. Goel, A. et al. DAMTC regulates cytoskeletal reorganization and cell motility in human lung adenocarcinoma cell line: an integrated proteomics and transcriptional approaches. *Cell Death Dis.* 3, e402 (2012).

**Acknowledgements**

This work was supported by Grants from Council of Scientific and industrial research (CSIR) Task-force project ‘Genome Dynamics in Cellular Organization, Differentiation and Enantioptosis (Decoding the function of Non-Coding RNA, GENCODE)’ (Grant BSC-0123). Richa Singh, Vikas Yadav was supported with CSIR-Senior Research Fellowship & Sachin Kumar was supported with CSIR-Junior Research Fellowship.
Author Contributions
R.S., V.Y. and N.S. conceived and designed the study. R.S., V.Y., S.K. performed the experiments. R.S. and N.S. performed the bioinformatic analysis. R.S., V.Y. and N.S. analysed the data and wrote the paper.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Singh, R. et al. MicroRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1. Sci. Rep. 5, 17454; doi: 10.1038/srep17454 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/